scholarly article | Q13442814 |
P50 | author | Huifang Zong | Q97094408 |
Jianrong Xu | Q97094409 | ||
P2093 | author name string | Hua Jiang | |
Kai Ding | |||
Tao Sun | |||
Jianwei Zhu | |||
Lei Han | |||
Cedric Cagliero | |||
Baohong Zhang | |||
Yueqing Xie | |||
Xinyu Zhang | |||
Jiaxian Wang | |||
P2860 | cites work | Crystal structure of mammalian alpha1,6-fucosyltransferase, FUT8 | Q24337064 |
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
Improving the efficacy of antibody-based cancer therapies | Q28208361 | ||
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity | Q30835165 | ||
Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. | Q33985245 | ||
Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications | Q34223494 | ||
Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity | Q34346238 | ||
Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia | Q34989602 | ||
Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma | Q35222112 | ||
Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer | Q35698114 | ||
Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. | Q36366519 | ||
Protein A chromatography for antibody purification | Q36618496 | ||
Glycosylation as a strategy to improve antibody-based therapeutics | Q37402407 | ||
Cell engineering and cultivation of chinese hamster ovary (CHO) cells. | Q37704492 | ||
Mammalian cell protein expression for biopharmaceutical production | Q37941925 | ||
Therapeutic antibodies: market considerations, disease targets and bioprocessing | Q37974006 | ||
Targeting the human epidermal growth factor receptor 2 in esophageal cancer | Q38097675 | ||
Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. | Q38255828 | ||
Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density | Q38328896 | ||
CRISPR/Cas9-mediated genome engineering of CHO cell factories: Application and perspectives | Q38522356 | ||
Production process reproducibility and product quality consistency of transient gene expression in HEK293 cells with anti-PD1 antibody as the model protein | Q38730765 | ||
CRISPR-Cas targeted plasmid integration into mammalian cells via non-homologous end joining | Q38878854 | ||
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines | Q39447473 | ||
Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies. | Q39690283 | ||
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance | Q40109415 | ||
Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma | Q40401124 | ||
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity | Q40690773 | ||
Core fucosylation of IgG B cell receptor is required for antigen recognition and antibody production | Q41395654 | ||
Marketing approval of mogamulizumab: a triumph for glyco-engineering | Q42333453 | ||
Accelerating genome editing in CHO cells using CRISPR Cas9 and CRISPy, a web-based target finding tool | Q43125635 | ||
The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum. | Q45987354 | ||
Biacore surface matrix effects on the binding kinetics and affinity of an antigen/antibody complex. | Q51538929 | ||
Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system | Q58547271 | ||
Donor substrate binding and enzymatic mechanism of human core α1,6-fucosyltransferase (FUT8) | Q84976737 | ||
P433 | issue | 7 | |
P304 | page(s) | 801-808 | |
P577 | publication date | 2017-04-18 | |
P1433 | published in | Engineering in Life Sciences | Q15752832 |
P1476 | title | Producing defucosylated antibodies with enhanced in vitro antibody-dependent cellular cytotoxicity via FUT8 knockout CHO-S cells | |
P478 | volume | 17 |
Q93452631 | CHO-S FUT8-/- | described by source | P1343 |
Search more.